Akari Therapeutics and Peak Bio Inc. announced a merger to create Akari Therapeutics, Plc, focusing on Oncology, Autoimmune and Inflammatory diseases

The merged pipeline integrates an advanced ADC toolkit with novel payload and linker technologies, blending chemotherapy and immunotherapy to develop innovative cancer solutions. It also features a pre-clinical ADC targeting TROP-2 for expanded treatment options

The transaction involves an all-stock exchange, expected to result in approximately 50% ownership for both Akari and Peak shareholders, with closing anticipated in the late second quarter, subject to customary approvals

The merged company is expected to prioritize BD&L initiatives with significant patient impact, boasting a diverse pipeline